All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Sanofi's Teizeild (teplizumab) receives CHMP approval recommendation for stage 2 type 1 diabetes treatment
Antibody, autoimmune, monoclonal antibody, type 1 diabetes, CD3 target - Read more

Otsuka's HAE drug Dawnzera wins EU regulatory endorsement following 81% attack reduction in trials
Antisense oligonucleotide, rare disease, regulatory, strategic - Read more

FDA approves Henlius' Poherdy (pertuzumab-dpzb), first interchangeable biosimilar to Roche's Perjeta for HER2-positive breast cancer
Antibody, cancer, monoclonal antibody, breast cancer, HER2 target, biosimilar - Read more

THE GOOD
Business Development & Partnerships

PRISM BioLab achieves initial milestone + milestone payment in oncology drug discovery collaboration with Ono Pharmaceutical using PepMetics technology
Research collaboration, oncology, small molecule, drug discovery, milestone payments - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Eisai presents 48-month lecanemab (leqembi) data showing sustained benefits in early Alzheimer's disease patients
Antibody, neurological, monoclonal antibody, Alzheimer disease, amyloid beta, apolipoprotein - Read more

Egetis reports positive Ph3 results for Emcitate (tiratricol) targeting MCT8 deficiency, plans NDA submission
Small molecule, metabolic, MCT8 deficiency, thyroid hormone analog, orphan disease - Read more

THE GOOD
Fundraises

Medicxi closes $579M sixth fund for asset-centric biotech investing
Venture capital, life sciences, asset-centric investing - Read more

Sofinnova Partners raises $750M flagship fund, early-stage biotech medtech investments
Venture capital, biotech, medtech, early-stage - Read more

TandemAI raises $22M Series A extension, AI-powered drug discovery platform development
AI/ML platform, drug discovery, platform technology, computational drug design - Read more

ABL Bio raises $16M strategic investment from Eli Lilly, advancing Grabody platform
Antibody, bispecific ADCs, platform technology, oncology - Read more

Virometix raises $15M funding, pneumococcal vaccine development using synthetic virus-like particles
Infectious disease, vaccine development, platform technology, clinical-stage - Read more

Verastem Oncology raises $90M public offering, RAS/MAPK pathway-driven cancer treatments
Oncology, RAS/MAPK pathway, biopharmaceutical, cancer - Read more

THE GOOD
Lawsuits

US judge approves Purdue Pharma's $7.4B opioid settlement ending thousands of lawsuits
Small molecule, pain management, financial, major transaction, operational - Read more

THE GOOD
Mergers & Acquisitions

Merck & Co. acquires Cidara Therapeutics for $9.2B to gain late-stage universal flu prevention drug CD388
Drug-Fc conjugate, infectious disease, strategic, major transaction - Read more

Biocon considers $4.5B merger with biosimilars unit Biocon Biologics, evaluating IPO options
Biosimilars, strategic, major transaction, financial - Read more

Lundbeck offers $21/share for Avadel, outbidding Alkermes' $18.50 deal for narcolepsy drug Lumryz
Small molecule, neurological, strategic, major transaction - Read more

THE BAD
Business Development & Partnerships

Pfizer reportedly planning to divest BioNTech stake worth approximately $500 million
Divestiture, vaccine, mRNA, equity investment - Read more

THE BAD
Clinical Trials

Bristol Myers Squibb discontinues Ph3 trial of milvexian for acute coronary syndrome after interim futility analysis
Small molecule, cardiovascular, factor XIa inhibitor, acute coronary syndrome, anticoagulant - Read more

THE BAD
Layoffs

Bayer CEO says workforce cuts will slow to "incremental" levels after 13,500 layoffs since 2024
Operational, cost reduction, strategic, organizational restructuring - Read more

Charles River Laboratories lays off 70 staff, relocates production in strategic shift toward animal testing alternatives
Animal testing alternatives, operational, strategic, cost reduction - Read more

Sensei cuts 65% of workforce, terminates three executives amid financial struggles and strategic review
Monoclonal antibody, oncology, cost reduction, operational, financial - Read more

THE BAD
Regulatory

Applied Therapeutics faces analyst skepticism over rare disease drug govorestat amid FDA regulatory delays
Small molecule, rare disease, regulatory, financial - Read more

FDA approves restrictive Elevidys label with boxed warning, limiting Sarepta's gene therapy to ambulatory patients
Gene therapy, rare disease, regulatory, operational - Read more

THE BAD
Strategic Plans

Merck & Co.'s Verona withdraws EU filing for COPD drug Ohtuvayre mid-review month after acquisition
Inhaled PDE3/4 inhibitor, respiratory, regulatory, strategic, major transaction - Read more

Cartesian pauses lupus development despite positive data, refocuses Descartes-08 on myositis and myasthenia gravis
Cell therapy, autoimmune, strategic, operational - Read more [Paywall]

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here